by Brendon Nafziger
, DOTmed News Associate Editor
Ion Beam Applications S.A.'s newly spun-off radiopharmaceutical wing IBA Molecular has inked a five-year deal with group purchasing organization Novation LLC to supply its member health care facilities with PET radiotracers.
Under the deal, announced Monday, IBA Molecular will supply imaging agents, including 18-Fluorodeoxyglucose, as well as provide educational and training services. The contract took effect July 1. Terms of the deal weren't disclosed.
Story Continues Below Advertisement
Dr. Steven Mendelsohn of Zwanger-Pesiri Radiology, explains his commitment to dose reduction and why he believes a change in attitudes will be driven by patients rather than radiology professionals. Click to read more>>>
IBA Molecular has 54 PET isotope facilities in Europe, North America and Asia. It also delivers agents for SPECT imaging worldwide.
SK Capital Partners holds a controlling stake in IBA Molecular, which was spun off from its Belgian parent company, which retains a minority stake, in April.